Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases

NCT02231710 is registered in ClinicalTrials.gov with Bellicum Pharmaceuticals as lead sponsor.

NCT NCT02231710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02231710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
Lead sponsor
Bellicum Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2015
Completion date
January 31, 2018
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemoglobinopathies, hemophagocytic lymphohistiocytosis, inherited bone marrow failure syndrome, metabolic disorders, primary immune deficiency disorders